PMID- 31618762
OWN - NLM
STAT- MEDLINE
DCOM- 20200127
LR  - 20200212
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 60
IP  - 13
DP  - 2019 Oct 1
TI  - Focal Thickness Reduction of the Ganglion Cell-Inner Plexiform Layer Best 
      Discriminates Prior Optic Neuritis in Patients With Multiple Sclerosis.
PG  - 4257-4269
LID - 10.1167/iovs.19-27574 [doi]
AB  - PURPOSE: The goal was to visualize topographic thickness maps of the intraretinal 
      layers and evaluate their discrimination abilities and relationships with 
      clinical manifestations in patients with multiple sclerosis (MS) and a history of 
      optic neuritis (ON). METHODS: Thirty patients with relapsing-remitting MS (34 
      eyes with a history of ON [MSON] and 26 non-ON fellow eyes [MSFE]) were recruited 
      together with 63 age- and sex-matched controls (HC). Ultrahigh resolution optical 
      coherence tomography was used to image the macula and the volumetric data set was 
      segmented to yield six intraretinal layers. Topographic thickness maps were 
      aligned and averaged for the visualization. The thickness maps were partitioned 
      using the Early Treatment Diabetic Retinopathy Study (ETDRS) and related to Sloan 
      low-contrast letter acuity (LCLA), Expanded Disability Status Scale (EDSS), and 
      disease duration. RESULTS: Focal thickness reduction occurred in the macular 
      retinal nerve fiber layer (mRNFL) and ganglion cell-inner plexiform layer 
      (GCIPL), with the most profound reduction occurring in MSON eyes (P < 0.05). A 
      horseshoe-like thickness reduction pattern (U Zone) in the GCIPL appeared in 
      MSON. The thickness of the U Zone had better discrimination power than the ETDRS 
      partitions (area under the curve = 0.97) and differentiated 96% of MSON from HC. 
      The thickness of the U Zone was positively correlated to 2.5% LCLA (r = 0.38, P < 
      0.05) and 1.25% LCLA (r = 0.57, P < 0.05). CONCLUSIONS: The horseshoe-like 
      thickness reduction of the GCIPL appeared to be an ON-specific focal thickness 
      alteration with the highest discrimination power of prior ON.
FAU - Hu, Huiling
AU  - Hu H
AD  - Shenzhen Key Laboratory of Ophthalmology, Shenzhen Eye Hospital, Jinan 
      University, Shenzhen, China.
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami 
      Miller School of Medicine, Miami, Florida, United States.
FAU - Jiang, Hong
AU  - Jiang H
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami 
      Miller School of Medicine, Miami, Florida, United States.
AD  - Department of Neurology, University of Miami Miller School of Medicine, Miami, 
      Florida, United States.
FAU - Gameiro, Giovana Rosa
AU  - Gameiro GR
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami 
      Miller School of Medicine, Miami, Florida, United States.
FAU - Hernandez, Jeffrey
AU  - Hernandez J
AD  - Department of Neurology, University of Miami Miller School of Medicine, Miami, 
      Florida, United States.
FAU - Delgado, Silvia
AU  - Delgado S
AD  - Department of Neurology, University of Miami Miller School of Medicine, Miami, 
      Florida, United States.
FAU - Wang, Jianhua
AU  - Wang J
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami 
      Miller School of Medicine, Miami, Florida, United States.
LA  - eng
GR  - P30 EY014801/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*pathology
MH  - Optic Neuritis/*pathology
MH  - Retina/pathology
MH  - Retinal Ganglion Cells/*pathology
MH  - Tomography, Optical Coherence
PMC - PMC6996667
EDAT- 2019/10/17 06:00
MHDA- 2020/01/28 06:00
PMCR- 2019/10/01
CRDT- 2019/10/17 06:00
PHST- 2019/10/17 06:00 [entrez]
PHST- 2019/10/17 06:00 [pubmed]
PHST- 2020/01/28 06:00 [medline]
PHST- 2019/10/01 00:00 [pmc-release]
AID - 2753187 [pii]
AID - IOVS-19-27574R3 [pii]
AID - 10.1167/iovs.19-27574 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4257-4269. doi: 
      10.1167/iovs.19-27574.